Zobrazeno 1 - 10
of 55
pro vyhledávání: '"35"'
Autor:
David H. Johnson, Roy S. Herbst, Corey J. Langer, Louis Fehrenbacher, William Novotny, Eric Holmgren, Jacques Gaudreault, John Nemunaitis, David M. Jablons, Fairooz F. Kabbinavar, Russell F. DeVore, Lisa A. Damico
Publikováno v:
Journal of Clinical Oncology. 41:2305-2312
Purpose To investigate the efficacy and safety of bevacizumab plus carboplatin and paclitaxel in patients with advanced or recurrent non-small-cell lung cancer. Patients and Methods In a phase II trial, 99 patients were randomly assigned to bevacizum
Autor:
Mark J. Ratain, Arlene A. Forastiere, Lei Ye, Robert F. Gagel, Ezra E.W. Cohen, Linda Janisch, Steven I. Sherman, Forlisa Nauling, David S. Hong, Chaan S. Ng, Razelle Kurzrock, Thomas Müller, Ranee Mehra, Douglas W. Ball, John W. Frye, David G. Pfister, Roger B. Cohen, Ravi Salgia
Publikováno v:
Journal of Clinical Oncology. 29:2660-2666
Purpose XL184 (cabozantinib) is a potent inhibitor of MET, vascular endothelial growth factor receptor 2 (VEGFR2), and RET, with robust antiangiogenic, antitumor, and anti-invasive effects in preclinical models. Early observations of clinical benefit
Publikováno v:
Journal of Clinical Oncology. 24:1454-1458
Purpose A previous report suggested the nadir serum CA-125 level within the group of patients with ovarian cancer who achieved normalization of CA-125 accurately defined the risk of relapse. Using similar CA-125 subgroups, we sought to determine if t
Autor:
Sylke Nagel, Aruna Raghavachar, Ludwig Fischer von Weikersthal, Monika Serke, Ernst-Wilhelm Schmidt, Christine Lautenschlaeger, Hans Schweisfurth, Wolfgang Schuette, Ina Dittrich, Klaus Hans, Thomas Blankenburg, Angelika Reißig
Publikováno v:
Journal of Clinical Oncology. 23:8389-8395
Purpose A phase III study to determine whether a weekly docetaxel schedule improves the therapeutic index compared with the classic 3-weekly schedule. Patients and Methods Patients with stage IIIB-IV non–small-cell lung cancer (NSCLC) were randomly
Publikováno v:
Journal of Clinical Oncology. 16:1844-1848
PURPOSE Both paclitaxel and carboplatin have single-agent activity against carcinoma of the urothelium. We evaluated the combination of paclitaxel and carboplatin in the treatment of advanced cancers of the urothelium. PATIENTS AND METHODS Patients w
Autor:
Matthew A. Williams, Robert B. Livingston, G. K. Ellis, C A Long, R White, C McGuirt, Julie R. Gralow, B B Adamkiewicz
Publikováno v:
Journal of Clinical Oncology. 15:1395-1400
PURPOSE We evaluated weekly single-agent intravenous (IV) vinorelbine as salvage therapy for metastatic breast cancer. After the first five patients, all received elective growth factor support with granulocyte colony-stimulating factor (G-CSF; filgr
Autor:
John C. Ruckdeschel, P. Bonomi, Antonio C. Wolff, Donna Neuberg, David H. Johnson, David S. Ettinger, Robert L. Comis
Publikováno v:
Journal of Clinical Oncology. 13:1615-1622
PURPOSE A phase II study of ifosfamide, carboplatin, and prolonged oral administration of etoposide (ICE) in patients with untreated extensive-disease (ED) small-cell lung cancer (SCLC) was conducted to assess toxicities, response, and median surviva
Autor:
E I Smith, Bennett L. Leventhal, Vijay V. Joshi, Donald H. Mahoney, Robert P. Castleberry, R L Berkow, Alexander A. Green, Alan B. Cantor, George R. Buchanan, F A Hayes
Publikováno v:
Journal of Clinical Oncology. 12:1616-1620
PURPOSE Children less than 1 year of age with metastatic neuroblastoma NB are at high risk of death. The need to identify new and effective chemotherapy agents is clear. A study was conducted by the Pediatric Oncology Group (POG) to determine the eff
Autor:
Richard G. Hahn, Lawrence H. Einhorn, Paul Elson, Richard D. Williams, Patrick J. Loehrer, Robert Dreicer, Craig R. Nichols
Publikováno v:
Journal of Clinical Oncology. 12:483-488
PURPOSE This multicenter cooperative group phase I/II trial evaluated the toxicity and efficacy of escalated dosages of methotrexate, vinblastine, doxorubicin, and cisplatin (M-VAC) with recombinant human granulocyte colony-stimulating factor (rhG-CS
Autor:
T M Waits, Mary L. McMaster, F A Greco, John D. Hainsworth, Richard S. Stein, S. N. Wolff, David H. Johnson, John P. Greer
Publikováno v:
Journal of Clinical Oncology. 11:943-949
PURPOSE Despite substantial advances in the treatment of aggressive non-Hodgkin's lymphoma, therapeutic results with conventional regimens remain poor in some subsets of patients. In an attempt to improve the prognosis of such patients we used an 8-w